Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.

[1]  B. Tombal,et al.  Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. , 2002, Urology.

[2]  A W Partin,et al.  Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. , 2002, Urology.

[3]  D. Johnston,et al.  Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml. , 2001, The Journal of urology.

[4]  I. Sugano,et al.  Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. , 2001, Anticancer research.

[5]  A W Partin,et al.  Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. , 2000, The Journal of urology.

[6]  J. Richie,et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. , 2000, Urology.

[7]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[8]  J. Richie,et al.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. , 1999, The Journal of urology.

[9]  D. Chan,et al.  Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay , 1999, The International journal of biological markers.

[10]  A. Zlotta,et al.  Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml. , 1998, The Journal of urology.

[11]  M. Brawer,et al.  Measurement of complexed PSA improves specificity for early detection of prostate cancer. , 1998, Urology.

[12]  A W Partin,et al.  The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer. , 1998, Seminars in urologic oncology.

[13]  P. Humphrey,et al.  Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. , 1998, Urology.

[14]  P. Humphrey,et al.  The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer. , 1998, The Journal of urology.

[15]  J. Pannek,et al.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer. , 1998, The Journal of urology.

[16]  K. Fujita,et al.  Transition Zone Volume-Adjusted Prostate-Specific Antigen Value Predicts Extracapsular Carcinoma of the Prostate in Patients with Intermediate Prostate-Specific Antigen Levels , 1998, European Urology.

[17]  D. Ornstein,et al.  Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. , 1997, The Journal of urology.

[18]  D. Ornstein,et al.  Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. , 1997, JAMA.

[19]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[20]  D. Ornstein,et al.  Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. , 1997, The Journal of urology.

[21]  J. Pannek,et al.  The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. , 1996, Urology.

[22]  J. Oesterling,et al.  Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. , 1996, Urology.

[23]  D. Bostwick,et al.  Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.

[24]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[25]  D. Chan,et al.  The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. , 1990, The Journal of urology.

[26]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.